fda glp-1 enforcement news october 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Compound versions of GLP-1 drugs

This product combines a complex of 5 enzymes alpha-amylase, lactase, protease, lipase and cellulase each specifically targeting a macronutrient to facilitate its breakdown

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to t

If your plan hard-excludes GLP-1 medication, cash-pay is often faster than appealing

November 25, 2025 PRESSADVANTAGE LifeRx.md announced that it has implemented reduced pricing for its personalized GLP-1 and GIP treatment programs, a development the organization states is intended to align with the federal governments ongoing pursuit of nationwide affordability measures for these treatments

What they found was cost dominates treatment decisions: 68% said cost influenced their decision to start or continue treatment 44% said the medication cost more than they expected Cost surpassed side effects as the #1 reason people stopped taking GLP-1s A breakdown of the financial burden: 24% pay more than $250 per prescription fill Nearly 8% pay $500 or more per fill 24% said insurance didn't cover any cost Weight management patients were nearly twice as likely to pay $250+ vs diabetes patients --- Here's what patients are thinking: Nearly 40% ended up using discount programs or manufacturer coupons 60% know someone who wants GLP-1s but can't afford them 83% believe Americans turn to DTC programs because traditional healthcare is too expensive Patients still prioritize safety: 60% are aware of safety risks with non-FDA-approved GLP-1s--this one surprised me

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely used in the treatment of metabolic disorders, including type 2 diabetes (T2D) and obesity